Strides Pharma Science Ltd Stock Price Today (NSE: STAR)

Strides Pharma Science Ltd

1106.90+4.20 (+0.38%)
Market Open

Fundamental Score

...

Strides Pharma Science Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Strides Pharma Science Ltd share price today is 1106.90, up +0.38% on NSE/BSE as of 17 June 2026. Strides Pharma Science Ltd (STAR) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of 8.41K (Cr). The 52-week high for STAR share price is 1231.00 and the 52-week low is 768.65. At a P/E ratio of 19.35x, STAR is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 150.67% and a debt-to-equity ratio of 0.67.

Strides Pharma Science Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
1231.00
Low
1017.10
Volume
3.9L
Change
+4.41%

Strides Pharma Science Ltd share price chart: 4.41% return over the past month. 52-week high ₹1231.00, 52-week low ₹768.65.

Strides Pharma Science Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
1094.001094.101060.301075.002.14L (Cr)
1111.801136.301086.401094.101.89L (Cr)
1157.701168.801089.001111.805.19L (Cr)
1179.201188.001149.601154.401.80L (Cr)
1188.101207.601161.001169.202.75L (Cr)
1144.001195.001144.001188.102.59L (Cr)
1159.201169.701137.901153.201.50L (Cr)
1160.301173.301131.101159.102.19L (Cr)
1152.501210.801131.501141.706.45L (Cr)
1124.001159.001035.001153.6013.25L (Cr)

Strides Pharma Science Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
1111.801136.301060.301075.00-3.31%
1053.301231.001017.101111.80+5.55%
956.001107.00925.001036.80+8.45%
820.10952.85817.25937.75+14.35%
855.00912.00812.00851.55-0.40%
906.351010.30768.65877.00-3.24%
886.95973.90836.75900.35+1.51%
934.401025.00870.60878.40-5.99%
820.00978.40792.00934.70+13.99%
864.50936.00786.80820.60-5.08%
873.00935.00783.15863.70-1.07%
899.65972.00861.05874.10-2.84%

Returns & Performance

Excellent

Return on Equity (ROE)

150.67%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

14.68%

Returns generated on total capital deployed

Average

Oper. Profit Margin (5Y Avg)

10.16%

Average operating profit margin over 5 years

Dividend Yield

0.44%

Annual dividend as % of current share price

Strides Pharma Science Ltd Valuation Check

Excellent

Price to Earnings (P/E)

19.35x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

31.77x

Average P/E of all peers in this sector

Market-cap Classification
Mid-cap
Balance of growth potential and stability.

Shareholding Pattern

Excellent

Promoter Holding

27.86%

% shares held by company founders/management

Excellent

FII Holding

28.51%

% shares held by foreign institutional investors

Good

DII Holding

12.98%

% held by domestic mutual funds, LIC, banks

Poor

Promoter Pledged %

44.13%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

79.67%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

4.62%

Revenue growth vs same quarter last year

Average

Revenue Growth (5-Year CAGR)

10.65%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

122.76%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

124.04%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Poor

Debt to Equity Ratio

0.67x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

3.77x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

1.00K (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Strides Pharma Science Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of STAR across key market metrics for learning purposes.

Positive Indicators

7 factors identified

Strong Return on Equity (150.67%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Attractive Valuation (P/E: 19.35 vs Industry: 31.77)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Robust Profit Growth (79.67%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Excellent EPS Growth (122.76% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (124.04% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Strong Cash Generation (₹1000.52 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Strong Institutional Confidence (FII+DII: 41.49%)

Observation: Significant professional investor participation.

Analysis: High institutional holding often signals thorough due diligence.

Risk Factors

2 factors identified

Low Promoter Commitment (27.86%)

Observation: Reduced promoter stake may indicate limited confidence.

Analysis: Low promoter holding may raise questions about management commitment.

High Share Pledging Risk (44.13%)

Observation: Significant promoter share pledging creates potential overhang.

Analysis: High pledging levels may create selling pressure during market downturns.

Strides Pharma Science Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Strides Pharma Science Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
31.7/100
1107
₹8407.98
19.4
Average
150.67%
Excellent
14.68%
Average
0.7
Good
124.04%
Excellent
10.65%
Good
0.44%
65.2/100
1844
₹433738.68
37.6
Average
16.86%
Good
20.21%
Excellent
0.1
Excellent
23.78%
Excellent
9.87%
Good
0.89%
67.9/100
6798
₹170445.88
68.6
Average
15.35%
Good
20.44%
Excellent
0.0
Excellent
10.41%
Good
11.65%
Good
0.47%
65.3/100
4538
₹126430.62
58.4
Average
26.52%
Excellent
27.05%
Excellent
0.3
Excellent
13.84%
Good
7.72%
Good
0.86%
Cipla Ltd...
CIPLA500087
59/100
1418
₹123059.76
22.6
Average
17.77%
Good
22.72%
Excellent
0.0
Excellent
28.68%
Excellent
9.97%
Good
0.85%
59.2/100
1319
₹105224.96
18.2
Average
17.96%
Good
22.69%
Excellent
0.2
Excellent
22.28%
Excellent
13.26%
Good
0.63%
Lupin Ltd...
LUPIN500257
66.7/100
2276
₹95148.15
22.0
Average
20.62%
Excellent
21.30%
Excellent
0.3
Excellent
54.88%
Excellent
8.11%
Good
0.58%
68.7/100
957
₹94253.78
18.7
Average
21.21%
Excellent
24.31%
Excellent
0.4
Excellent
25.92%
Excellent
10.27%
Good
1.17%
50.6/100
2420
₹92012.53
52.6
Average
14.68%
Average
15.98%
Good
0.6
Good
11.73%
Good
15.79%
Excellent
0.04%
28.8/100
1436
₹70798.69
20.7
Average
11.08%
Average
14.18%
Average
0.2
Excellent
3.87%
Average
6.55%
Good
0.33%
59.5/100
5452
₹67075.29
28.5
Average
19.39%
Good
20.38%
Excellent
0.2
Excellent
13.93%
Good
9.21%
Good
0.80%

Strides Pharma Science Ltd PE Ratio History

Historical price-to-earnings ratio for STAR — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 2025390.50₹900.352.3x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Strides Pharma Science Ltd Dividend History

Annual cash dividends paid by STAR — dividend yield 0.44%

Financial YearDividends Paid (₹ Cr)
FY 202522.99 Cr
FY 202413.52 Cr
FY 202222.43 Cr
FY 202117.91 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Strides Pharma Science Ltd Quarterly Performance

Latest quarterly metrics for STAR — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

4.62%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

79.67%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

10.65%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

124.04%

Compounded annual net profit growth over 5 years

Strides Pharma Science Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for STAR — calculated from daily price history

53RSI 14
Neutral — RSI 53

Momentum is balanced — neither overbought nor oversold.

SMA 50
1034
▲ Price above SMA 50 — Short-term bullish
SMA 200
915
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
377K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Strides Pharma Science Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Strides Pharma Science Ltd (STAR) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Strides Pharma Science Ltd

About STAR (Strides Pharma Science Ltd)

Strides Pharma Science Ltd is a global pharmaceutical entity carving a niche through its broad spectrum of development, manufacturing, and commercialization of diverse pharmaceutic...al products. It operates across a wide geographical footprint, strategically positioning itself in key markets across Africa, Australia, North America, Europe, and Asia. The company excels in producing a comprehensive range of finished dosage forms, catering to various therapeutic needs through an array of product formats. This includes everything from conventional tablets and capsules, both hard and soft gelatin, to more specialized formulations like sachets, liquids, nasal sprays, gels, and topical treatments like ointments and creams. This multifaceted approach allows Strides to effectively meet the demands of diverse patient populations and healthcare providers worldwide. Beyond its generic offerings, Strides Pharma is actively involved in the development and marketing of branded generic products, focusing on therapeutic areas with significant growth potential and unmet medical needs. The company has a particular emphasis on chronic therapies, addressing long-term health conditions that require sustained treatment and management. These strategic therapeutic areas encompass women's health, recognizing the specific healthcare needs of women across different life stages, and the central nervous system, targeting neurological and psychiatric disorders. Furthermore, Strides is committed to developing solutions for cardiovascular ailments, reflecting the increasing prevalence of heart-related diseases globally. This focus on branded generics allows Strides to differentiate itself in the market and provide value-added products for both patients and prescribers. Strides Pharma's strength lies in its ability to integrate research and development, manufacturing excellence, and strategic commercial partnerships to deliver high-quality pharmaceutical products to a global audience. Its vertically integrated structure, encompassing API sourcing, formulation development, and commercialization, enables efficient cost management and robust quality control. The company's commitment to innovation, coupled with its deep understanding of regulatory landscapes across various markets, allows it to navigate the complexities of the pharmaceutical industry effectively. By continuously adapting to evolving market dynamics and investing in future growth opportunities, Strides Pharma Science is positioned to sustain its momentum and expand its reach in the years to come.

Company Details

Symbol:STAR
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Arun Kumar Pillai B.Com.
Founder & Non-Executive Chairperson
Mr. Badree Komandur
MD & Group CEO
Mr. Vikesh Kumar
Group CFO

STAR Share Price: Frequently Asked Questions

What is the current share price of Strides Pharma Science Ltd?

Strides Pharma Science Ltd (STAR) trades at ₹1106.90 on NSE and BSE. Market cap ₹8.41K (Cr). Educational data only.

What is the P/E ratio of Strides Pharma Science Ltd?

Strides Pharma Science Ltd has a P/E of 19.35x vs industry average 31.77x.

What is the Bull Run score for Strides Pharma Science Ltd?

Strides Pharma Science Ltd has a Bull Run score of 31.7/100 based on 25+ financial parameters.

Does Strides Pharma Science Ltd pay dividends?

Strides Pharma Science Ltd has a dividend yield of 0.44%. Past dividends don't guarantee future payments.

What is the ROE of Strides Pharma Science Ltd?

Strides Pharma Science Ltd has ROE of 150.67%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Strides Pharma Science Ltd?

Strides Pharma Science Ltd has debt-to-equity of 0.67.

Is Strides Pharma Science Ltd a good investment?

Bull Run gives Strides Pharma Science Ltd a score of 31.7/100. This is not investment advice — consult a SEBI-registered advisor.